The concern of generic competition has long loomed around copyright’s famous drug, Viagra, sparking questions read more about the prospects of related medicinal portfolios. While first periods saw significant gains, the exclusivity end has opened the door for discounted alternatives, likely lowering earnings and posing a real risk for shareholder